This content is only available within our institutional offering.
29 Jul 2019
Pharmaceuticals: AbbVie: Read-across from Q2 figures for European companies
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | AstraZeneca PLC (AZN:LON), 10,953 | GSK plc (GSK:LON), 1,600 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 4,620
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Pharmaceuticals: AbbVie: Read-across from Q2 figures for European companies
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | AstraZeneca PLC (AZN:LON), 10,953 | GSK plc (GSK:LON), 1,600 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 4,620
- Published:
29 Jul 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
Pharmaceuticals
AbbVie: Read-across from Q2 figures for European companies
No inflexion in Venclexta’s sequential growth
First sales booked for Skyrizi
Biosimilars Humira continue to grab shares ex-US